In 2006, a Japanese researcher named Shinya Yamanaka demonstrated that you could take an adult skin cell—fully differentiated, fully committed to being a skin cell for the rest of its existence—and rewind it to a state resembling an embryonic stem cell by introducing just four transcription factors. Four proteins. That’s it. The cell forgot it was old. It forgot it was skin. It reverted to something pluripotent, capable of becoming virtually anything. Yamanaka won the Nobel Prize for this in 2012, and the finding launched an entire field of research organized around a question that would have gotten you laughed out of a biology department twenty years earlier: can you reverse aging?
The answer, as of March 2026, is: in cells, yes. In mice, increasingly yes. In humans, we just started the first clinical trial, and we have no idea yet whether it works or whether it gives you cancer. That’s the honest state of play, and it’s simultaneously more exciting and more uncertain than either the hype or the skepticism suggests.
What aging actually is (the version that matters for reversal)
The dominant framework in aging biology right now is the epigenetic information theory of aging, most prominently articulated by David Sinclair at Harvard. The argument: aging is not primarily about DNA damage. Your DNA sequence stays remarkably stable over a lifetime—mutations accumulate, but they’re not the main driver. What degrades is the epigenome—the system of chemical modifications (primarily DNA methylation and histone modifications) that tells each cell which genes to turn on and which to keep silent. Think of your DNA as a piano. Every cell has the same piano. What makes a liver cell different from a neuron is which keys are being played. The epigenome is the sheet music. Over time, the sheet music accumulates errors—smudges, missing notes, wrong accidentals—and the cell starts playing the wrong song. It doesn’t lose the piano. It loses the instructions for what to play on it.
A 2023 paper in Cell from Sinclair’s lab provided the strongest evidence to date for this model, showing that deliberately introducing epigenetic noise into young mice—without mutating their DNA—produced aging phenotypes: gray fur, frailty, cognitive decline. And critically, they showed that introducing the Yamanaka factors (specifically three of the four: OCT4, SOX2, and KLF4, collectively called OSK—they drop the fourth, c-MYC, because it’s an oncogene and including it dramatically increases cancer risk) could reverse those epigenetic changes and restore youthful gene expression patterns.
The cell doesn’t need new parts. It needs its existing instructions cleaned up. That’s the core insight, and it’s why the field has pivoted from “slow aging down” to “reverse aging”—because if the problem is corrupted software rather than broken hardware, you might be able to restore from backup.
What’s been demonstrated in mice
The mouse data is where the story shifts from theoretical to tangible, and where the press release detector needs to be most finely calibrated—because the results are genuinely impressive and also genuinely far from clinical application.
Partial reprogramming—temporarily activating the Yamanaka factors (OSK or OSKM) without letting the cell fully revert to a pluripotent state—has been shown in multiple studies to reverse age-related changes in mice. The keyword is “partial.” Full reprogramming turns an adult cell into something resembling an embryonic stem cell, which is scientifically fascinating and medically terrifying because pluripotent cells form teratomas—tumors composed of disorganized tissue from multiple cell lineages, the kind of pathology that makes oncologists lose sleep. The trick is to activate the reprogramming factors just long enough to clean up the epigenetic noise but not so long that the cell loses its identity entirely. It’s the biological equivalent of rebooting your computer without wiping the hard drive.
A study published in Cellular Reprogramming delivered OSK via adeno-associated virus (AAV) to 124-week-old mice—the equivalent of roughly 80-year-old humans—and found that the median remaining lifespan increased by 109 percent. The treated mice also showed improvements in frailty markers, grip strength, and other health parameters. That’s not extending life at the cost of quality. That’s old mice getting measurably younger and then living dramatically longer.
Other approaches are converging on the same target from different angles. Senolytics—drugs that selectively kill senescent cells, the “zombie cells” that stop dividing but refuse to die and instead pump out inflammatory signals that damage surrounding tissue—have shown a 36 percent lifespan extension in mouse models. The Mayo Clinic team led by James Kirkland published the first senolytic results in 2011, and the field has since produced multiple drug candidates. Combining senolytics with partial reprogramming may be synergistic—a 2025 study in Drosophila showed that Yamanaka factors alone extended lifespan but didn’t dramatically improve healthspan, while adding a senolytic peptide compressed the mortality curve significantly. Kill the zombie cells, then rejuvenate the remaining ones. Belt and suspenders.
Caloric restriction—the oldest and most boring intervention in aging research—still works in mice. It’s been known since the 1930s. Eat less, live longer. The mechanism appears to involve activation of sirtuins, AMPK pathways, and reduced mTOR signaling, all of which overlap with the pathways targeted by more exotic interventions. The field sometimes forgets to mention that the intervention with the longest track record and the most robust data is “eat less food,” probably because it’s harder to build a biotech company around that pitch than around epigenetic reprogramming.
What’s happening in humans
This is where the gap between the press release and the reality becomes a canyon.
In late January 2026, Life Biosciences received FDA clearance to begin a Phase 1 human trial of ER-100, a gene therapy that delivers OSK (the three Yamanaka factors minus the oncogene) to treat age-related eye diseases—specifically non-arteritic anterior ischemic optic neuropathy and open-angle glaucoma. This is the first human trial of a cellular age-reversal technique. The therapy is based on David Sinclair’s work showing that OSK delivery to damaged retinal ganglion cells in mice could restore vision in aged animals. Enrollment began in early 2026, with initial dosing to follow and approximately two months of safety monitoring per cohort.
This is genuinely historic. But it’s Phase 1—the phase designed to answer the question “does this kill people?” not “does this work?” The trial is enrolling a small number of patients with specific eye diseases, not healthy aging adults. The endpoint is safety, not rejuvenation. If everything goes perfectly, we’ll have preliminary safety data by late 2026 or early 2027, and it’ll take years of additional trials to determine efficacy. Anyone telling you that age reversal therapy is available or imminent is selling something.
YouthBio Therapeutics is pursuing a different application of the same underlying technology—a gene therapy using Yamanaka factors to treat Alzheimer’s disease by partially reprogramming brain cells. In September 2025, they completed an INTERACT meeting with the FDA, which supported their plans to move toward a first-in-human trial. They’re not there yet—they’re doing CMC work and pilot toxicology studies—but the pathway is being laid.
Senolytics are further along clinically. Rubedo Life Sciences’ RLS-1496 entered Phase 1 in 2025 for actinic keratosis—a common precancerous skin condition—with plans for broader age-related applications in 2026. Unity Biotechnology has run trials targeting knee osteoarthritis and diabetic macular edema. The senolytic approach is more pharmaceutically conventional than gene therapy—you’re giving a patient a drug that kills specific cells, which is a framework that regulatory agencies understand well—and it’s likely to reach the market before reprogramming-based therapies.
How we measure any of this
One of the most important developments in aging biology isn’t a therapy—it’s a measurement tool. Epigenetic clocks, pioneered by Steve Horvath at UCLA, measure biological age by analyzing DNA methylation patterns at specific sites across the genome. Your chronological age is how many birthdays you’ve had. Your biological age, as measured by an epigenetic clock, is how old your cells’ methylation patterns look compared to a reference database. These two numbers can diverge significantly—a 50-year-old with the epigenetic age of a 40-year-old is biologically younger than the calendar says, and vice versa.
Epigenetic clocks are what allow researchers to claim that an intervention has “reversed aging” in a quantifiable way. When Sinclair’s lab says OSK reduced the epigenetic age of retinal cells, they’re using Horvath-type clocks to measure the before and after. When senolytics researchers report age reversal, same tool. The clocks aren’t perfect—there’s ongoing debate about which methylation sites matter most and whether the clocks measure aging itself or just correlates of aging—but they’ve given the field something it never had before: a biomarker that can detect changes in biological age over weeks or months rather than requiring decades of follow-up to see whether someone actually lived longer.
What’s still hard
The cancer risk is the elephant in the room. The Yamanaka factors are transcription factors that activate genes involved in cellular proliferation and dedifferentiation. c-MYC is a known oncogene. OCT4, SOX2, and KLF4 are not officially oncogenes, but they regulate pathways that, if overactivated, push cells toward uncontrolled growth. The entire partial reprogramming field is built on the premise that you can activate these factors just enough to rejuvenate but not enough to cause tumors. In mice, this has been demonstrated repeatedly. In humans, we have no data yet. The Phase 1 trials will be the first real test.
Delivery is the second problem. Getting Yamanaka factors into cells throughout an entire organism—not just the eye, not just one organ—requires systemic gene therapy delivery, which is a problem that the gene therapy field has been working on for thirty years and has not fully solved. AAV vectors have tissue tropisms—they preferentially infect certain organs. Getting comprehensive, even distribution of a reprogramming payload across all tissue types in a human body is an unsolved engineering challenge.
Durability is the third. Nobody knows how long partial reprogramming effects last. If you rejuvenate a mouse’s cells at 124 weeks, are they still rejuvenated at 150 weeks, or does the epigenetic noise re-accumulate? If the treatment needs to be repeated, how often? What are the cumulative risks of repeated exposure to potent transcription factors? These are questions that require long-term data we don’t have and won’t have for years.
The honest forecast
The science of aging reversal is real, it’s advancing rapidly, and it has produced results in animal models that would have been considered science fiction a decade ago. Mice that are biologically old becoming biologically young is not a metaphor—it’s a measured, replicated observation. The first human trials are underway. The tools to measure biological age exist and are improving. The investment is substantial—Altos Labs alone raised $3 billion with Yamanaka himself as an advisor.
But “reverse aging” as a phrase currently describes a research direction, not a product. The first human applications will be narrow—specific diseases of the eye, specific joint conditions, specific skin pathologies—not whole-body rejuvenation. The path from “Phase 1 for an eye disease” to “take this pill and get younger” is measured in decades, not years, and involves clearing safety hurdles that have not yet been attempted. The people who will benefit first will be patients with age-related diseases that currently have no good treatment, not healthy 50-year-olds looking to turn back the clock.
That’s not a reason for pessimism. It’s a reason for calibrated expectations—which is what good science requires and what press releases consistently fail to deliver.
We cover the reversal of biological aging—Yamanaka factors, senolytics, epigenetic clocks, caloric restriction, and every other approach currently in play—in depth in our Moonshot 2169 course, which dedicates an entire lecture to the science, the constraints, and the timeline for when any of this might actually reach a clinic near you.